JSH-23 functions as an NF-κB inhibitor, effectively suppressing NF-κB transcriptional activity with an IC50 of 7.1 μM in lipopolysaccharide (LPS)-stimulated macrophages RAW 264.7. It achieves this by impeding the nuclear translocation of NF-κB p65 without impacting IκBα degradation[1].
体内研究
JSH-23 (1 mg/kg and 3 mg/kg; orally administered; daily; for 2 weeks) significantly mitigates nerve conduction and nerve blood flow deficits observed in diabetic rats[2].
体外研究
When administered at concentrations below 100 μM for 24 hours, JSH-2 does not induce significant cytotoxic effects on RAW 264.7 cells[1].
Upon exposure to LPS for 1 hour, the nuclear content of NF-κB p65 significantly increases. Treatment with JSH-23 (30 μM; 1 hour) reduces the nuclear content of NF-κB p65 in LPS-stimulated RAW 264.7 cells in a dose-dependent manner[1].
JSH-23 reduced the TWEAK-enhanced Ro52 expression, indicating that the NF-κB pathway is involved in the TWEAK regulation of Ro52.
Front Immunol. 2017 May 31;8:651.
T98G cells
200 µM
48 h
To evaluate the effect of JSH-23 on T98G cells, results showed that JSH-23 significantly inhibited cell proliferation and induced apoptosis.
Clin Transl Immunology. 2022 May 9;11(5):e1393.
LN229 cells
200 µM
48 h
To evaluate the effect of JSH-23 on LN229 cells, results showed that JSH-23 significantly inhibited cell proliferation and induced apoptosis.
Clin Transl Immunology. 2022 May 9;11(5):e1393.
JSH-23 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Mice
CLP-induced sepsis model
Intraperitoneal injection
20 mg/kg
2 hours before CLP and 12, 24, 48, and 72 hours after CLP
To evaluate the therapeutic effect of JSH-23 on sepsis, the results showed that JSH-23 improved organ injury but did not significantly improve survival rate
Cell Death Dis. 2022 Jul 28;13(7):653
Mice
MCD-induced NASH model
Oral gavage
3 mg/kg
Once daily for 4 weeks
JSH-23 prevented MCD-induced upregulation of caspase-11 mRNA and protein expression
To evaluate the effect of JSH-23 on trauma-induced heterotopic ossification. The results showed that JSH-23 significantly reduced the senescent cell burden at the injury site and inhibited the eventual heterotopic ossification formation.
Adv Sci (Weinh). 2023 Jul;10(19):e2207383
BALB/c nude mice
Tumor xenograft model
Intraperitoneal injection
5 mg/kg
Once daily for 15 days
To investigate whether PBK enhances olaparib resistance in ovarian cancer through the NF-κB pathway, results showed that JSH-23 blocked the resistance induced by PBK overexpression
Exp Mol Med. 2022 Jul;54(7):999-1010
Nude mice
GBM xenograft model
Intraperitoneal injection
25 mg/kg
Every 2 days for 21 days
To evaluate the effect of JSH-23 on the GBM xenograft model, results showed that JSH-23 significantly inhibited tumor growth.
Clin Transl Immunology. 2022 May 9;11(5):e1393.
Mice
Mmp14/C0//C0 mice
Intraperitoneal injection
10 mg/kg
Daily for 12 days
JSH-23 significantly reduces corneal lymphangiogenesis in Mmp14/C0//C0 mice by inhibiting NF-κB signaling pathway
搜索
